Case Details
- Citation: [2023] SGHC 345
- Title: The Enterprise Fund III Ltd and another v CNPLaw LLP (formerly known as Colin Ng & Partnership)
- Court: High Court of the Republic of Singapore (General Division)
- Suit No: 355 of 2021
- Date of Judgment: 7 December 2023
- Judges: Choo Han Teck J
- Hearing Dates: 24–26 October; 24 November 2023
- Judgment Reserved: Yes
- Plaintiffs/Applicants: (1) The Enterprise Fund III Ltd (EFIII) (2) Value Monetization III Ltd (VMIII)
- Defendant/Respondent: CNPLaw LLP (formerly known as Colin Ng & Partnership) (CNP)
- Legal Area: Tort – Negligence (lawyers’ breach of duty)
- Statutes Referenced: Companies Act (Cap 50, 2006 Rev Ed)
- Key Statutory Provision (as described): s 76(1A)(a) of the Companies Act (prohibition against a company buying its own shares)
- Related Proceedings Mentioned: OS 380 of 2017; Suit 357 of 2021; prior suits culminating in Court of Appeal decision (not fully reproduced in extract)
- Cases Cited: [2018] SGHC 246; [2023] SGHC 345 (as per metadata; the latter is the present case)
- Judgment Length: 14 pages, 4,281 words
Summary
This High Court decision concerns a claim by two investment funds (the “Lenders”) against their solicitors, CNPLaw LLP (“CNP”), for alleged professional negligence in relation to a loan facility agreement used in a transaction that was later held to be void. The underlying transaction involved a borrower’s acquisition of its own shares indirectly through a structure in which the Lenders advanced funds to the borrower and the borrower’s funds were used to purchase its shares on the open market. The Court of Appeal had previously held that the entire transaction was void because it violated the statutory prohibition on a company buying its own shares under s 76(1A)(a) of the Companies Act.
In the present action, the Lenders alleged that CNP failed to properly advise them about the legal implications of s 76(1A)(a) and the risk that the facility and related share purchases would be void. The Lenders further contended that CNP’s pleaded position was inconsistent with its trial position, and that this inconsistency supported an inference that CNP had not provided adequate advice.
The court rejected the claim. It found that there was no material inconsistency in CNP’s defence and that the evidence supported CNP’s narrative that, at the material time, CNP was not informed that the loan facility monies would be used to purchase the borrower’s shares. The court also accepted that CNP had been aware of the risk of a share buyback purpose during drafting, but that the final “purpose” clause was changed to “general working capital” and that the Lenders’ evidence did not establish that CNP had failed in its duty to advise on the s 76 issue in the manner alleged.
What Were the Facts of This Case?
The first plaintiff, The Enterprise Fund III Ltd (“EFIII”), is a Singapore-incorporated fund that provides financing to small and medium-sized enterprises that cannot obtain bank financing. The second plaintiff, Value Monetization III Ltd (“VMIII”), is incorporated in the British Virgin Islands. Both funds are managed by Crest Capital Asia Fund Management Pte Ltd (“Crest”). Mr Peter Chan (“Mr Chan”) was a director and investment committee member of the Lenders, while Mr Glendon Tan (“Glendon Tan”) headed Crest’s Enterprise Fund division and was responsible for managing EFIII. Mr Lim Chu Pei (“Mr Lim”) assisted with transactions involving EFIII.
CNP were the Lenders’ solicitors for Crest and its affiliates from 2008. Mr Steven Soh (“Mr Soh”) was a partner at CNP from 2007 and co-headed the corporate finance team with Ms Tan Min-Li (“Ms Tan”) between 2017 and 2019. Mr Soh left CNP in April 2021 after suffering a stroke. Ms Tan was head of corporate and finance from 2002. Mr Loh Yong Hui (“Mr Loh”) was an associate of about two years’ standing in the corporate finance practice at CNP during the material period and assisted Mr Soh and Ms Tan.
The Lenders’ loss arose from a flawed loan facility agreement executed in 2015 with International Healthway Corporation Ltd (now OUE Lippo Healthcare Ltd) (the “Borrower”). The agreement was first drawn up on 6 April 2015, with changes, and was finally executed on 21 July 2015 but backdated to 16 April 2015. The facility’s stated purpose was “to be utilised by the [Borrower] for general working capital.” The agreement was later refinanced and superseded by another substantially similar facility agreement on 30 July 2015, extending the facility. The facts about the agreement’s execution and its general purpose were not disputed.
What became critical, however, was how the facility funds were actually used. EFIII used the loan facility funds to purchase shares in the Borrower in the open market at about 29 cents per share, for a total of $17,332,081.15. The shares were bought between 16 April 2015 and 24 August 2015. EFIII purported to hold the shares in trust for the Borrower. In September 2015, the Singapore Exchange issued a notice of suspicious trading activities relating to the Borrower’s shares. The Borrower defaulted, and in October 2015 CNP was instructed to demand repayment. In January 2017, the Borrower replaced its board, and on 8 March 2017 it repudiated the facility agreement on the basis of illegality. Proceedings were commenced on 6 April 2017 (OS 380 of 2017), and the Lenders’ appeal was dismissed.
The Court of Appeal held that the entire transaction—comprising the loan facility, the open market purchase, and the trust declarations—was void because it violated s 76(1A)(a) of the Companies Act, which prohibits a company from buying its own shares. The Lenders then faced further consequences. The Borrower had paid $700,000 under the vitiated facility agreement and $3,800,000 towards another loan facility (the “Geelong” facility). The Lenders refused to treat the $3,800,000 as payment towards the Geelong facility and instead treated it as payment under the vitiated facility, leading the Borrower to refuse further payment to the Geelong facility. The Borrower’s Australian properties were placed in receivership and sold.
After losing in the related suits, the Lenders were left holding the Borrower’s shares acquired using the facility monies, which were worth far less than the original purchase price. EFIII then commenced Suit 357 of 2021 against Glendon Tan, its manager at the material time. Glendon Tan brought a third-party claim against Mr Chan and CNP. Glendon Tan’s defence to EFIII’s claim was that he had no knowledge of any illegal activity and that the person in charge was Mr Chan. Suit 357 was settled between EFIII and Glendon Tan, and Glendon Tan discontinued his third-party claim against Mr Chan and CNP. The present action (Suit 355 of 2021) therefore continued to trial.
What Were the Key Legal Issues?
The central legal issue was whether CNP owed and breached a duty of care to the Lenders in advising on the loan facility and its legal implications, particularly the risk arising from s 76(1A)(a) of the Companies Act. The Lenders framed their claim as one of negligence: they alleged that CNP failed to properly advise them about the impact of the statutory prohibition on the transaction structure and that this failure was causative of their losses.
A second key issue concerned the evidential and pleading alignment between CNP’s position and its trial evidence. The Lenders argued that there was a material inconsistency: CNP pleaded that it did not know the facility monies were used to purchase the Borrower’s shares, but at trial CNP’s position was that it had been told of the initial intention to use the facility for a share purchase and had advised against it. The Lenders contended that, because CNP did not plead that it had advised on the s 76 issue and that such advice was ignored, CNP should not be allowed to rely on an alternative narrative to defeat causation and breach.
Third, the court had to assess whether the Lenders had proved their case on the balance of probabilities, given that the Lenders’ evidence relied heavily on Mr Chan, who had no personal knowledge of the relevant matters, and that Glendon Tan—the person most directly involved—was not called as a witness in the present action.
How Did the Court Analyse the Issues?
The court began by addressing the alleged inconsistency. It held that there was no material inconsistency between CNP’s pleaded defence and its trial position. The court accepted CNP’s explanation that its pleaded case was that it did not know the facility monies were ultimately used to purchase the Borrower’s shares. At trial, CNP’s evidence was that it had advised against the Lenders’ initial intention to use the facility for a share buyback, but that it subsequently accepted the Lenders’ instructions that the facility was for working capital. On that basis, CNP did not know that the facility money was in fact used for the share purchase. The court reasoned that this trial position was consistent with the pleaded position because the pleaded case concerned knowledge of the actual use of the funds, not necessarily the existence of an earlier intention.
Having resolved the inconsistency argument, the court turned to whether CNP had indeed advised against using the loan facility for the purposes of purchasing the Borrower’s shares, and more broadly whether CNP had failed to discharge its duty to advise on the s 76 issue. The court emphasised that the negligence claim depended on proof of breach and causation, and that the Lenders’ case required evidence that CNP had not provided the relevant advice at the relevant time.
On the evidence, the court found support for CNP’s narrative that the loan facility was not for the purposes of purchasing the Borrower’s shares and was meant for general working capital. The court relied on documentary evidence from the drafting stage. It noted that from the beginning of the engagement with CNP (around 5 or 6 April 2015), the documentary record suggested that CNP was aware of the risk that a loan facility might be used for a share buyback by the borrower. In particular, on 6 April 2015, Mr Loh sent a first draft of the agreement to Mr Soh, observing that, as per discussions with Mr Soh, the loan was sought from Crest for the Borrower “to undertake action to support its share price.” At that stage, “general working capital” had not yet been inserted as the purpose of the loan agreement.
The court further noted that Mr Loh followed up with a second draft later that day, with questions such as “what is the purpose of the loan, share buyback by [the Borrower]?” The purpose clause was left blank with a marking indicating it would be filled later. This drafting history, in the court’s view, was consistent with CNP’s account that it was aware of the initial purpose and the associated risks. It also supported the conclusion that CNP had not been operating in ignorance of the possibility of a share buyback purpose during the drafting process.
In addition, the court accepted Mr Soh’s account that after receiving Mr Loh’s email about clarifying the purpose of the loan, he would have called Glendon to clarify the position and that Glendon would have told him to reflect that the purpose of the loan was to finance the Borrower’s working capital. The court’s reasoning indicates that the court treated the drafting and clarification process as a key factual bridge: it showed that CNP was alerted to the share buyback risk, sought clarification, and then proceeded on the basis that the purpose was working capital. On that basis, the court concluded that the Lenders had not established that CNP failed to advise them about the s 76 implications in the manner alleged.
Although the extract provided is truncated, the court’s approach is clear from the portions reproduced: it assessed credibility and documentary support, weighed the absence of key witnesses called by the Lenders, and refused to infer negligence merely from the fact that the transaction later turned out to be void. The court’s analysis reflects a standard negligence framework: the claimant must prove duty, breach, and causation, and where the evidence shows that the solicitor acted on instructions and sought clarification, the claimant must show that the solicitor nonetheless failed to meet the relevant standard of care.
What Was the Outcome?
The court dismissed the Lenders’ claim against CNP. In practical terms, the decision meant that the Lenders could not shift the loss arising from the void transaction onto their solicitors through a negligence claim. The court’s findings on (i) the absence of a material inconsistency in CNP’s defence and (ii) the sufficiency of evidence supporting CNP’s narrative were decisive.
Accordingly, the Lenders remained without recovery from CNP for the losses associated with the void loan facility and the resulting shareholding position. The decision also underscores that, in solicitor negligence claims, the claimant must establish not only that the underlying transaction was legally defective, but also that the solicitor failed in the relevant duty of advice and that such failure caused the loss.
Why Does This Case Matter?
This case is significant for practitioners because it illustrates how Singapore courts approach solicitor negligence claims arising from complex financing structures later found to be void. The fact that a transaction violates a statutory prohibition does not automatically establish that solicitors were negligent. Instead, the claimant must prove what the solicitor knew, what instructions were given, what advice was (or was not) provided, and how that advice related to the statutory risk.
From a litigation strategy perspective, the decision also highlights the importance of evidence. The court was persuaded by documentary records created during the drafting process and by the coherence of CNP’s narrative. Conversely, the Lenders’ reliance on witnesses with limited personal knowledge, and the absence of the key dealing person (Glendon Tan) from the witness box in the present action, weakened their ability to prove breach and causation.
Finally, the case is a useful reference point on pleading and trial consistency. The court’s treatment of the alleged inconsistency demonstrates that courts will not treat every difference between pleaded and trial positions as fatal. Where the trial position can be reconciled with the pleaded case—particularly where the pleaded case is about knowledge of actual use rather than earlier intentions—courts may accept the solicitor’s explanation and decline to draw adverse inferences.
Legislation Referenced
- Companies Act (Cap 50, 2006 Rev Ed), s 76(1A)(a) (prohibition against a company buying its own shares)
Cases Cited
- [2018] SGHC 246
- [2023] SGHC 345
Source Documents
This article analyses [2023] SGHC 345 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.